Moleculin Biotech, INC. 8-K Filing
Ticker: MBRX · Form: 8-K · Filed: Nov 12, 2025 · CIK: 1659617
Sentiment: neutral
Filing Stats: 531 words · 2 min read · ~2 pages · Grade level 10.4 · Accepted 2025-11-12 09:02:42
Filing Documents
- mbrx20251110_8k.htm (8-K) — 29KB
- ex_885770.htm (EX-99.1) — 14KB
- m01.jpg (GRAPHIC) — 6KB
- m02.jpg (GRAPHIC) — 6KB
- 0001437749-25-034263.txt ( ) — 203KB
- mbrx-20251112.xsd (EX-101.SCH) — 3KB
- mbrx-20251112_def.xml (EX-101.DEF) — 12KB
- mbrx-20251112_lab.xml (EX-101.LAB) — 15KB
- mbrx-20251112_pre.xml (EX-101.PRE) — 12KB
- mbrx20251110_8k_htm.xml (XML) — 3KB
01
Item 7.01 Regulation FD Disclosure On November 12, 2025, Moleculin Biotech, Inc. (the "Company"), issued a press release which announced it has entered into research and material transfer agreement with the University of North Carolina at Chapel Hill (UNC) for investigator-initiated preclinical research evaluating Annamycin for the treatment of pancreatic cancer. A copy of the press release is attached to this report as Exhibit 99.1 and is incorporated by reference herein. The information contained in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, is being furnished and shall not be "filed" for the purpose of the Securities Exchange Act of 1934, as amended ("Exchange Act"), nor shall it be incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended ("Securities Act"), unless specifically identified therein as being incorporated by reference.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press Release dated November 12, 2025 104 Cover page Interactive Data File (formatted as Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. MOLECULIN BIOTECH, INC. Date: November 12, 2025 By: /s/ Jonathan P. Foster Jonathan P. Foster